{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:07Z","timestamp":1792798327485,"version":"4.5.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Abatacept plus calcineurin inhibitors\/methotrexate (CNI\/MTX) is the first US Food and Drug Administration (FDA)-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantation (URD-HCT). Using Center for International Blood and Marrow Transplant Research data, we investigated its impact in patients receiving 7\/8 HLA-mismatched unrelated donor (MMUD) or 8\/8 HLA-matched unrelated donor (MUD) URD-HCT between 2011 and 2018. Primary outcomes included day-180, 1-year, and 2-year overall survival (OS) and relapse-free survival (RFS) for abatacept\u00a0+ CNI\/MTX vs\u00a0CNI\/MTX, CNI\/MTX\u00a0+ antithymocyte globulin (ATG), and posttransplant cyclophosphamide-based prophylaxis (PT-Cy). For 7\/8 MMUDs, day-180 OS (primary end point supporting FDA approval) was significantly higher for abatacept\u00a0+ CNI\/MTX vs CNI\/MTX (98% vs 75%; P\u00a0=\u00a0.0028). Two-year RFS was significantly higher for abatacept\u00a0+ CNI\/MTX vs CNI\/MTX (74% vs 49%; P\u00a0=\u00a0.0098) and CNI\/MTX\u00a0+ ATG (77% vs 35%; P\u00a0=\u00a0.0002), and similar vs PT-Cy (72% vs 56%; P\u00a0=\u00a0.1058). For 8\/8 MUDs, 2-year RFS for abatacept\u00a0+ CNI\/MTX was numerically higher vs CNI\/MTX (63% vs 52%; P\u00a0=\u00a0.1497), with an improved hazard ratio (HR) of 0.46 (0.25-0.86), and vs CNI\/MTX\u00a0+ ATG (66% vs 55%; P\u00a0=\u00a0.1193; HR, 0.39 [0.21-0.73]), and was similar vs PT-Cy (68% vs 57%; P\u00a0=\u00a0.2356; HR, 0.54 [0.26-1.11]). For 7\/8 MMUD and 8\/8 MUD recipients, abatacept\u00a0+ CNI\/MTX prophylaxis improved survival outcomes vs CNI\/MTX and CNI\/MTX\u00a0+ ATG; outcomes were similar to PT-Cy\u2013based regimens. Abatacept\u00a0+ CNI\/MTX may facilitate unrelated donor pool expansion for HCT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023660","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T18:58:33Z","timestamp":1721415513000},"page":"1834-1845","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation"],"prefix":"10.1182","volume":"144","author":[{"given":"Leslie S.","family":"Kean","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, MA"},{"name":"2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"3Pediatrics, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda J.","family":"Burns","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzuyung D.","family":"Kou","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne","family":"Kapikian","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"},{"name":"6Cytel Inc, Waltham, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karissa","family":"Lozenski","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0649-1915","authenticated-orcid":false,"given":"Amelia","family":"Langston","sequence":"additional","affiliation":[{"name":"7Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Horan","sequence":"additional","affiliation":[{"name":"8Department of Pediatrics, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Watkins","sequence":"additional","affiliation":[{"name":"9Hematology and Oncology, Tulane University School of Medicine, New Orleans, LA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"10Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, and Department of Pediatrics, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1001","authenticated-orcid":false,"given":"Brandi","family":"Bratrude","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Betz","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ying","family":"Tang","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-861X","authenticated-orcid":false,"given":"Sean E.","family":"Connolly","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Polinsky","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Gavin","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gomez-Caminero","sequence":"additional","affiliation":[{"name":"5Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1579-2293","authenticated-orcid":false,"given":"Marcelo C.","family":"Pasquini","sequence":"additional","affiliation":[{"name":"4Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin Clinical Cancer Center, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2024102415210424800_bib1","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/bloodadvances.2018028662","article-title":"Racial\u00a0disparities in access to HLA-matched unrelated donor transplants: a prospective 1312-patient analysis","volume":"3","author":"Barker","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"2024102415210424800_bib2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"2024102415210424800_bib3","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"19","key":"2024102415210424800_bib4","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood-2010-01-261958","article-title":"Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors","volume":"116","author":"Shaw","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2024102415210424800_bib5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"2024102415210424800_bib6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024102415210424800_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","article-title":"HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation","volume":"17","author":"Woolfrey","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024102415210424800_bib8","doi-asserted-by":"crossref","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"key":"2024102415210424800_bib9","doi-asserted-by":"crossref","first-page":"100792","DOI":"10.1016\/j.blre.2020.100792","article-title":"Graft-versus-host disease prophylaxis: pathophysiology-based review on current approaches and future directions","volume":"48","author":"Martinez-Cibrian","year":"2021","journal-title":"Blood Rev"},{"issue":"12","key":"2024102415210424800_bib10","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2012.703652","article-title":"Prevention of graft-vs.-host disease","volume":"13","author":"Rezvani","year":"2012","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"2024102415210424800_bib11","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2024102415210424800_bib12","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.13977","article-title":"Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation","volume":"173","author":"Mehta","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2024102415210424800_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"issue":"25","key":"2024102415210424800_bib14","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024102415210424800_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-020-2138-x","article-title":"Cytotoxic T\u00a0lymphocyte-associated antigen-4-Ig (CTLA-4-Ig) suppresses Staphylococcus aureus-induced CD80, CD86, and pro-inflammatory cytokine expression in human B cells","volume":"22","author":"Liu","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2024102415210424800_bib16","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"7","key":"2024102415210424800_bib17","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3899\/jrheum.200154","article-title":"Absence of association between abatacept exposure and initial infection in patients with juvenile idiopathic arthritis","volume":"48","author":"Ruperto","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"2024102415210424800_bib18","author":"US Food and Drug Administration","year":"2021"},{"key":"2024102415210424800_bib19","unstructured":"ORENCIA\u00ae (abatacept)\n          . Package insert. Bristol Myers Squibb; 2024. Accessed 17 April 2023. http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf."},{"issue":"17","key":"2024102415210424800_bib20","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2024102415210424800_bib21","unstructured":"Center For International Blood And Marrow Transplant Research (CIBMTR)\n          . Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries. Accessed 7 September 2022. https:\/\/www.cibmtr.org\/DataManagement\/ProtocolConsent\/ObservationalData\/Documents\/2022%2006%2027%20Research%20Database%20Protocol%20v9.1.pdf."},{"issue":"suppl 1","key":"2024102415210424800_bib37","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2021-150742","article-title":"Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following 7\/8 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation: analysis of the Center for International Blood and Marrow Transplant Research Database","volume":"138","author":"Kean","year":"2021","journal-title":"Blood"},{"issue":"suppl","key":"2024102415210424800_bib38","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1016\/S2666-6367(22)00564-4","article-title":"Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following allogeneic hematopoietic stem cell transplantation: analysis of the Center for International Blood and Marrow Transplant Research Database","volume":"3","author":"Kean","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024102415210424800_bib39","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood-2022-157610","article-title":"A real-world evidence comparison of 1-year overall survival and relapse-free survival between patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate versus antithymocyte globulin or post-transplant cyclophosphamide following allogeneic hematopoietic cell transplantation","volume":"140","author":"Kean","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024102415210424800_bib40","first-page":"OS05","article-title":"Survival outcomes at 1-year post-allogeneic HCT between patients treated with abatacept in combination with CNI+MTX versus ATG or PT-Cy: a real-world evidence comparison","volume":"58","author":"Kean","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"2024102415210424800_bib22","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1182\/blood.V83.12.3815.3815","article-title":"In\u00a0vivo blockade of CD28\/CTLA4: B7\/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the\u00a0major histocompatibility complex barrier\u00a0in mice","volume":"83","author":"Blazar","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2024102415210424800_bib23","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.bbmt.2013.09.003","article-title":"In\u00a0vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial","volume":"19","author":"Koura","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2024102415210424800_bib24","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2010-06-289272","article-title":"GVHD after haploidentical transplantation: a novel, MHC-defined rhesus macaque model identifies CD28- CD8+ T cells as a reservoir of breakthrough T-cell proliferation during costimulation blockade and sirolimus-based immunosuppression","volume":"116","author":"Miller","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2024102415210424800_bib25","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI98793","article-title":"CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates","volume":"128","author":"Watkins","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2024102415210424800_bib26","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00007890-200002150-00027","article-title":"Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate\/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model","volume":"69","author":"Yu","year":"2000","journal-title":"Transplantation"},{"issue":"4","key":"2024102415210424800_bib27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/TP.0000000000003327","article-title":"Graft-versus-host disease prophylaxis with abatacept reduces severe acute graft-versus-host disease in allogeneic hematopoietic stem cell transplant for beta-thalassemia major with busulfan, fludarabine, and thiotepa","volume":"105","author":"Khandelwal","year":"2021","journal-title":"Transplantation"},{"issue":"16","key":"2024102415210424800_bib28","first-page":"3894","article-title":"Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease","volume":"4","author":"Ngwube","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024102415210424800_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MPH.0000000000002421","article-title":"Abatacept-based graft-versus-host disease prophylaxis in haplo-identical hematopoietic cell transplant in a high-risk cohort","volume":"44","author":"Raffa","year":"2022","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"suppl 2","key":"2024102415210424800_bib30","article-title":"Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN","volume":"140","author":"Holtan","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024102415210424800_bib31","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1182\/blood-2023-188032","article-title":"Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: results of the BMT CTN 1801 study","volume":"142","author":"Kean","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024102415210424800_bib32","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2022.12.017","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024102415210424800_bib33","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1182\/bloodadvances.2021005208","article-title":"Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation","volume":"6","author":"Qayed","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2024102415210424800_bib34","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2024102415210424800_bib35","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.1182\/blood-2022-163627","article-title":"Abatacept for the prevention of GvHD in pediatric and adult patients receiving 7\/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis","volume":"140","author":"Raghunandan","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2024102415210424800_bib36","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2022008545","article-title":"Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure","volume":"7","author":"Stenger","year":"2023","journal-title":"Blood Adv"},{"key":"2024102415210424800_bib41","unstructured":"Center for International Blood and Marrow Transplant Research (CIBMTR). Our Centers. Accessed 6 August 2024. https:\/\/www.cibmtr.org\/About\/WhoWeAre\/Centers\/Pages\/index.aspx."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/17\/1834\/2246931\/blood_bld-2023-023660-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/17\/1834\/2246931\/blood_bld-2023-023660-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:21:20Z","timestamp":1729783280000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/17\/1834\/517112\/Abatacept-for-acute-graft-versus-host-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,10,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023660","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}